基于图表的视觉功能测试在年龄相关性黄斑变性患者中的重复性与区分能力:MACUSTAR研究报告
这项国际非干预性研究在18个欧洲三级眼科中心纳入301名受试者,评估5种基于图表的视觉功能测试在中期年龄相关性黄斑变性(iAMD)中的重复性与区分能力。结果显示所有测试重复性良好至优秀(ICC 0.88-0.96),区分iAMD与晚期AMD能力优秀(AUC 0.92-0.99),但区分无AMD与iAMD能力有限(CS最佳AUC 0.77)。
要点
- 5种基于图表的视觉功能测试在iAMD中显示出良好至优秀的重复性(ICC 0.88-0.96)。
- 所有测试区分iAMD与晚期AMD能力优秀(AUC 0.92-0.99)。
- 区分无AMD与iAMD能力有限,CS最佳(AUC 0.77),IReST较差(AUC 0.57-0.61)。
核心结论
- BCVA、LLVA、MAT、CS和IReST在多中心、多检查者环境下具有足够的重复性,但区分无AMD与iAMD的能力有限。
- 这些变量预测从iAMD向晚期AMD转化的预后能力正在MACUSTAR研究的纵向部分中进行考察。
研究设计与样本
- 国际非干预性研究,在18个欧洲三级眼科部门开展,受试者于2018年4月至2020年3月期间招募。
- 采用重复测量设计,于第0天和第14天进行视觉功能评估。
- 共纳入301名参与者(平均年龄71岁,标准差7岁;女性187名,占62.1%)。
- 参与者中早期AMD 34名(11.3%),iAMD 168名(55.8%),晚期AMD 43名(14.3%),无AMD 56名(18.6%)。
主要发现
- 所有参与者中,所有视觉功能测试的ICC在0.88至0.96之间,表明重复性良好至优秀。
- 所有测试区分iAMD与晚期AMD的AUC为0.92-0.99,区分能力优秀。
- 早期AMD与iAMD在所有测试上无法区分(AUC 0.54-0.64)。
- CS区分无AMD与iAMD的AUC为0.77,为最佳;BCVA、LLVA和MAT的AUC为0.69-0.71,区分能力一般;IReST的AUC为0.57-0.61,区分能力较差。
关键数值与推荐
- 重复性评估采用组内相关系数(ICC)和Bland-Altman 95%一致性界限(LoA)。
- 区分能力采用受试者工作特征曲线下面积(AUC)评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There is a need for validated clinical end points that are reliably able to quantify potential therapeutic effects of future treatments targeting age-related macular degeneration (AMD) before the onset of serious visual impairment. OBJECTIVE: To assess the reliability and discriminatory power of 5 simple chart-based visual function (VF) tests as potential measures for clinical trial end points with regulatory and patient-access intention in intermediate AMD (iAMD). DESIGN, SETTING, AND PARTICIPANTS: This international noninterventional study took place at 18 tertiary ophthalmology departments across Europe. Participants were recruited between April 2018 and March 2020 and were identified during routine clinical review. Participants with no AMD and early AMD were recruited from hospital staff, friends, and family of participants with AMD and via referrals from community ophthalmologists and optometrists. The repeatability and discriminatory power of 5 simple chart-based assessments of VF (best-corrected visual acuity [BCVA], low-luminance visual acuity [LLVA], Moorfields Acuity Test [MAT], Pelli-Robson Contrast Sensitivity [CS], and International Reading Speed Test [IReST]) were assessed in a repeated-measures design. VF assessments were performed on day 0 and day 14. Participants with early AMD, iAMD, late AMD, and no AMD were recruited. MAIN OUTCOMES AND MEASURES: Intraclass correlation coefficients (ICCs) and Bland-Altman 95% limits of agreement (LoA) were computed to assess repeatability. Area under the receiver operating characteristic curves (AUCs) determined the discriminatory ability of all measures to classify individuals as having no AMD or iAMD and to differentiate iAMD from its neighboring disease states. RESULTS: A total of 301 participants (mean [SD] age, 71 [7] years; 187 female participants [62.1%]) were included in the study. Thirty-four participants (11.3%) had early AMD, 168 (55.8%) had iAMD, 43 (14.3%) had late AMD, and 56 (18.6%) had no AMD. ICCs for all VF measures ranged between 0.88 and 0.96 when all participants were considered, indicating good to excellent repeatability. All measures displayed excellent discrimination between iAMD and late AMD (AUC, 0.92-0.99). Early AMD was indistinguishable from iAMD on all measures (AUC, 0.54-0.64). CS afforded the best discrimination between no AMD and iAMD (AUC, 0.77). Under the same conditions, BCVA, LLVA, and MAT were fair discriminators (AUC, 0.69-0.71), and IReST had poor discrimination (AUC, 0.57-0.61). CONCLUSIONS AND RELEVANCE: BCVA, LLVA, MAT, CS, and IReST had adequate repeatability in this multicenter, multiexaminer setting but limited power to discriminate between no AMD and iAMD. The prognostic power of these variables to predict conversion from iAMD to late AMD is being examined in the ongoing longitudinal part of the MACUSTAR study.
引用
- Dunbar HMP, Behning C, Abdirahman A, et al. Repeatability and Discriminatory Power of Chart-Based Visual Function Tests in Individuals With Age-Related Macular Degeneration: A MACUSTAR Study Report. JAMA Ophthalmol. 2022. PMID: 35737401. doi:10.1001/jamaophthalmol.2022.2113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。